Targeting NO/cGMP Signaling in the CNS for neurodegeneration and Alzheimer's disease

Current Medicinal Chemistry

Volumn 23, Issue 24, 2016, Pages 2770-2783

  Aissa, Manel Ben ^a   Lee, Sue H ^a   Bennett, Brian M ^b   Thatcher, Gregory R J ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Alzheimer's disease; CREB activation; Neuroprotection; NO cGMP signaling; Synaptic function

Indexed keywords

CALCIUM CALMODULIN DEPENDENT PROTEIN KINASE II; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYCLIC GMP; GUANYLATE CYCLASE; MITOGEN ACTIVATED PROTEIN KINASE; NITRIC OXIDE; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN;

ALLOSTERISM; ALZHEIMER DISEASE; ARTICLE; CENTRAL NERVOUS SYSTEM; COGNITION; DEGENERATIVE DISEASE; DRUG TARGETING; HUMAN; INTRACELLULAR SIGNALING; LEARNING; MEMORY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NONHUMAN; SECOND MESSENGER; ANTAGONISTS AND INHIBITORS; CHEMISTRY; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; SYNAPSE;

ALZHEIMER DISEASE; CENTRAL NERVOUS SYSTEM; CREB-BINDING PROTEIN; CYCLIC GMP; HUMANS; NEURODEGENERATIVE DISEASES; NEURONAL PLASTICITY; NITRIC OXIDE; PHOSPHORIC DIESTER HYDROLASES; SIGNAL TRANSDUCTION; SOLUBLE GUANYLYL CYCLASE; SYNAPSES;

EID: 84989153992     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673236661608     Document Type: Article

References (251)

1. Palmer, A. M. Neuroprotective therapeutics for Alzheimer's disease: progress and prospects. Trends Pharmacol. Sci., 2011, 32(3), 141-147.
2. Sambamurti, K.; Greig, N. H.; Utsuki, T.; Barnwell, E. L.; Sharma, E.; Mazell, C.; Bhat, N. R.; Kindy, M. S.; Lahiri, D. K.; Pappolla, M. A. Targets for AD treatment: conflicting messages from gamma-secretase inhibitors. J. Neurochem., 2011, 117(3), 359-374.
3. Sabbagh, J. J.; Kinney, J. W.; Cummings, J. L. Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications. Neurobiol. Aging, 2013, 34(1), 169-183.
4. Godyn, J.; Jonczyk, J.; Panek, D.; Malawska, B. Therapeutic strategies for Alzheimer's disease in clinical trials. Pharmacol. Rep., 2016, 68(1), 127-138.
5. Berk, C.; Sabbagh, M. N. Successes and failures for drugs in late-stage development for Alzheimer's disease. Drugs Aging, 2013, 30(10), 783-792.
6. Selkoe, D. J. Resolving controversies on the path to Alzheimer's therapeutics. Nat. Med., 2011, 17(9), 1060-1065.
7. Mangialasche, F.; Solomon, A.; Winblad, B.; Mecocci, P.; Kivipelto, M. Alzheimer's disease: clinical trials and drug development. Lancet Neurol., 2010, 9(7), 702-716.
8. Vassar, R. BACE1 inhibitor drugs in clinical trials for Alzheimer's disease. Alzheimers Res. Ther., 2014, 6(9), 89.
9. Panza, F.; Frisardi, V.; Imbimbo, B. P.; Capurso, C.; Logroscino, G.; Sancarlo, D.; Seripa, D.; Vendemiale, G.; Pilotto, A.; Solfrizzi, V. REVIEW: gamma-Secretase inhibitors for the treatment of Alzheimer's disease: The current state. CNS Neurosci. Ther., 2010, 16(5), 272-284.
10. Milnerwood, A. J.; Raymond, L. A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci., 2010, 33(11), 513-523.
11. Bagetta, V.; Ghiglieri, V.; Sgobio, C.; Calabresi, P.; Picconi, B. Synaptic dysfunction in Parkinson's disease. Biochem. Soc. Trans., 2010, 38(2), 493-497.
12. Schulz-Schaeffer, W. J. The synaptic pathology of alphasynuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia. Acta Neuropathol., 2010, 120(2), 131-143.
13. DiProspero, N. A.; Chen, E. Y.; Charles, V.; Plomann, M.; Kordower, J. H.; Tagle, D. A. Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J. Neurocytol., 2004, 33(5), 517-533.
14. Henstridge, C. M.; Pickett, E.; Spires-Jones, T. L. Synaptic pathology: A shared mechanism in neurological disease. Ageing Res. Rev., 2016, 28, 72-84.
15. DeKosky, S. T.; Scheff, S. W. Synapse loss in frontal cortex biopsies in Alzheimer's disease: correlation with cognitive severity. Ann. Neurol., 1990, 27(5), 457-464.
16. Terry, R. D.; Masliah, E.; Salmon, D. P.; Butters, N.; De-Teresa, R.; Hill, R.; Hansen, L. A.; Katzman, R. Physical basis of cognitive alterations in Alzheimer's disease: synapse loss is the major correlate of cognitive impairment. Ann. Neurol., 1991, 30(4), 572-580.
17. Selkoe, D. J. Alzheimer's disease is a synaptic failure. Science, 2002, 298(5594), 789-791.
18. Masliah, E.; Mallory, M.; Alford, M.; DeTeresa, R.; Hansen, L. A.; McKeel, D. W., Jr.; Morris, J. C. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology, 2001, 56(1), 127-129.
19. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; DeKosky, S. T.; Mufson, E. J. Synaptic alterations in CA1 in mild Alzheimer disease and mild cognitive impairment. Neurology, 2007, 68(18), 1501-1508.
20. Scheff, S. W.; Price, D. A.; Schmitt, F. A.; Mufson, E. J. Hippocampal synaptic loss in early Alzheimer's disease and mild cognitive impairment. Neurobiol. Aging, 2006, 27(10), 1372-1384.
21. Bertoni-Freddari, C.; Fattoretti, P.; Casoli, T.; Caselli, U.; Meier-Ruge, W. Deterioration threshold of synaptic morphology in aging and senile dementia of Alzheimer's type. Anal. Quant. Cytol. Histol., 1996, 18(3), 209-213.
22. Davies, C. A.; Mann, D. M.; Sumpter, P. Q.; Yates, P. O. A quantitative morphometric analysis of the neuronal and synaptic content of the frontal and temporal cortex in patients with Alzheimer's disease. J. Neurol. Sci., 1987, 78(2), 151-164.
23. Chapman, P. F.; White, G. L.; Jones, M. W.; Cooper-Blacketer, D.; Marshall, V. J.; Irizarry, M.; Younkin, L.; Good, M. A.; Bliss, T. V.; Hyman, B. T.; Younkin, S. G.; Hsiao, K. K. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat. Neurosci., 1999, 2(3), 271-276.
24. Jacobsen, J. S.; Wu, C. C.; Redwine, J. M.; Comery, T. A.; Arias, R.; Bowlby, M.; Martone, R.; Morrison, J. H.; Pangalos, M. N.; Reinhart, P. H.; Bloom, F. E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006, 103(13), 5161-5166.
25. Shankar, G. M.; Li, S.; Mehta, T. H.; Garcia-Munoz, A.; Shepardson, N. E.; Smith, I.; Brett, F. M.; Farrell, M. A.; Rowan, M. J.; Lemere, C. A.; Regan, C. M.; Walsh, D. M.; Sabatini, B. L.; Selkoe, D. J. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat. Med., 2008, 14(8), 837-842.
26. English, J. D.; Sweatt, J. D., A requirement for the mitogenactivated protein kinase cascade in hippocampal long term potentiation. J. Biol. Chem., 1997, 272(31), 19103-19106.
27. Vitolo, O. V.; Sant'Angelo, A.; Costanzo, V.; Battaglia, F.; Arancio, O.; Shelanski, M. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA, 2002, 99(20), 13217-13221.
28. Coultrap, S. J.; Freund, R. K.; O'Leary, H.; Sanderson, J. L.; Roche, K. W.; Dell'Acqua, M. L.; Bayer, K. U. Autonomous CaMKII mediates both LTP and LTD using a mechanism for differential substrate site selection. Cell Rep., 2014, 6(3), 431-437.
29. Costa, C.; Tozzi, A.; Siliquini, S.; Galletti, F.; Cardaioli, G.; Tantucci, M.; Pisani, F.; Calabresi, P. A critical role of NO/cGMP/PKG dependent pathway in hippocampal postischemic LTP: modulation by zonisamide. Neurobiol. Dis., 2011, 44(2), 185-191.
30. Puzzo, D.; Vitolo, O.; Trinchese, F.; Jacob, J. P.; Palmeri, A.; Arancio, O. Amyloid-beta peptide inhibits activation of the nitric oxide/cGMP/cAMP-responsive element-binding protein pathway during hippocampal synaptic plasticity. J. Neurosci., 2005, 25(29), 6887-6897.
31. Ping, J.; Schafe, G. E. The NO-cGMP-PKG signaling pathway coordinately regulates ERK and ERK-driven gene expression at pre-and postsynaptic sites following LTPinducing stimulation of thalamo-amygdala synapses. Neural. Plast., 2010, 2010, 540940.
32. Son, H.; Lu, Y. F.; Zhuo, M.; Arancio, O.; Kandel, E. R.; Hawkins, R. D. The specific role of cGMP in hippocampal LTP. Learn Mem., 1998, 5(3), 231-245.
33. Barco, A.; Alarcon, J. M.; Kandel, E. R. Expression of constitutively active CREB protein facilitates the late phase of long-term potentiation by enhancing synaptic capture. Cell, 2002, 108(5), 689-703.
34. Kida, S. A functional role for CREB as a positive regulator of memory formation and LTP. Exp. Neurobiol., 2012, 21(4), 136-140.
35. Benito, E.; Barco, A., CREB's control of intrinsic and synaptic plasticity: implications for CREB-dependent memory models. Trends Neurosci., 2010, 33(5), 230-240.
36. Dworkin, S.; Malaterre, J.; Hollande, F.; Darcy, P. K.; Ramsay, R. G.; Mantamadiotis, T. cAMP response element binding protein is required for mouse neural progenitor cell survival and expansion. Stem Cells, 2009, 27(6), 1347-1357.
37. Mizuno, M.; Yamada, K.; Maekawa, N.; Saito, K.; Seishima, M.; Nabeshima, T. CREB phosphorylation as a molecular marker of memory processing in the hippocampus for spatial learning. Behav. Brain Res., 2002, 133(2), 135-141.
38. Viola, H.; Furman, M.; Izquierdo, L. A.; Alonso, M.; Barros, D. M.; de Souza, M. M.; Izquierdo, I.; Medina, J. H. Phosphorylated cAMP response element-binding protein as a molecular marker of memory processing in rat hippocampus: effect of novelty. J. Neurosci., 2000, 20(23), RC112.
39. Barco, A.; Marie, H. Genetic approaches to investigate the role of CREB in neuronal plasticity and memory. Mol. Neurobiol., 2011, 44(3), 330-349.
40. Dash, P. K.; Hochner, B.; Kandel, E. R. Injection of the cAMP-responsive element into the nucleus of Aplysia sensory neurons blocks long-term facilitation. Nature, 1990, 345(6277), 718-721.
41. Yin, J. C.; Del Vecchio, M.; Zhou, H.; Tully, T., CREB as a memory modulator: induced expression of a dCREB2 activator isoform enhances long-term memory in Drosophila. Cell, 1995, 81(1), 107-115.
42. Bourtchuladze, R.; Frenguelli, B.; Blendy, J.; Cioffi, D.; Schutz, G.; Silva, A. J. Deficient long-term memory in mice with a targeted mutation of the cAMP-responsive elementbinding protein. Cell, 1994, 79(1), 59-68.
43. Uslaner, J. M.; Parmentier-Batteur, S.; Flick, R. B.; Surles, N. O.; Lam, J. S.; McNaughton, C. H.; Jacobson, M. A.; Hutson, P. H. Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology, 2009, 57(5-6), 531-538.
44. Hall, J.; Thomas, K. L.; Everitt, B. J. Fear memory retrieval induces CREB phosphorylation and Fos expression within the amygdala. Eur. J. Neurosci., 2001, 13(7), 1453-1458.
45. Tronson, N. C.; Wiseman, S. L.; Neve, R. L.; Nestler, E. J.; Olausson, P.; Taylor, J. R. Distinctive roles for amygdalar CREB in reconsolidation and extinction of fear memory. Learn Mem., 2012, 19(5), 178-181.
46. Swank, M. W. Phosphorylation of MAP kinase and CREB in mouse cortex and amygdala during taste aversion learning. Neuroreport., 2000, 11(8), 1625-1630.
47. Yuan, Q.; Harley, C. W.; Bruce, J. C.; Darby-King, A.; McLean, J. H. Isoproterenol increases CREB phosphorylation and olfactory nerve-evoked potentials in normal and 5-HT-depleted olfactory bulbs in rat pups only at doses that produce odor preference learning. Learn Mem., 2000, 7(6), 413-421.
48. Zhang, W.; Linden, D. J. The other side of the engram: experience-driven changes in neuronal intrinsic excitability. Nat. Rev. Neurosci., 2003, 4(11), 885-900.
49. Disterhoft, J. F.; Oh, M. M. Learning, aging and intrinsic neuronal plasticity. Trends Neurosci., 2006, 29(10), 587-599.
50. Mozzachiodi, R.; Byrne, J. H. More than synaptic plasticity: role of nonsynaptic plasticity in learning and memory. Trends Neurosci., 2010, 33(1), 17-26.
51. Bartolotti, N.; Segura, L.; Lazarov, O. Diminished CREinduced plasticity is linked to memory deficits in familial Alzheimer's disease Mice. J. Alzheimers Dis., 2015, 50(2), 477-489.
52. Pugazhenthi, S.; Wang, M.; Pham, S.; Sze, C. I.; Eckman, C. B. Downregulation of CREB expression in Alzheimer's brain and in Abeta-treated rat hippocampal neurons. Mol. Neurodegener., 2011, 6, 60.
53. Saura, C. A.; Valero, J. The role of CREB signaling in Alzheimer's disease and other cognitive disorders. Rev. Neurosci., 2011, 22(2), 153-169.
54. Lonze, B. E.; Ginty, D. D., Function and regulation of CREB family transcription factors in the nervous system. Neuron, 2002, 35(4), 605-623.
55. Mayr, B.; Montminy, M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol., 2001, 2(8), 599-609.
56. Vecsey, C. G.; Hawk, J. D.; Lattal, K. M.; Stein, J. M.; Fabian, S. A.; Attner, M. A.; Cabrera, S. M.; McDonough, C. B.; Brindle, P. K.; Abel, T.; Wood, M. A. Histone deacetylase inhibitors enhance memory and synaptic plasticity via CREB:CBP-dependent transcriptional activation. J. Neurosci., 2007, 27(23), 6128-6140.
57. Hawk, J. D.; Abel, T. The role of NR4A transcription factors in memory formation. Brain Res. Bull., 2011, 85(1-2), 21-29.
58. Perez-Cadahia, B.; Drobic, B.; Davie, J. R. Activation and function of immediate-early genes in the nervous system. Biochem. Cell Biol., 2011, 89(1), 61-73.
59. Vician, L.; Lim, I. K.; Ferguson, G.; Tocco, G.; Baudry, M.; Herschman, H. R. Synaptotagmin IV is an immediate early gene induced by depolarization in PC12 cells and in brain. Proc. Natl. Acad. Sci. USA, 1995, 92(6), 2164-2168.
60. McNulty, S. E.; Barrett, R. M.; Vogel-Ciernia, A.; Malvaez, M.; Hernandez, N.; Davatolhagh, M. F.; Matheos, D. P.; Schiffman, A.; Wood, M. A. Differential roles for Nr4a1 and Nr4a2 in object location vs. object recognition longterm memory. Learn Mem., 2012, 19(12), 588-592.
61. Bramham, C. R.; Messaoudi, E. BDNF function in adult synaptic plasticity: The synaptic consolidation hypothesis. Prog. Neurobiol., 2005, 76(2), 99-125.
62. Soule, J.; Messaoudi, E.; Bramham, C. R. Brain-derived neurotrophic factor and control of synaptic consolidation in the adult brain. Biochem. Soc. Trans., 2006, 34(Pt 4), 600-604.
63. Hall, J.; Thomas, K. L.; Everitt, B. J., Rapid and selective induction of BDNF expression in the hippocampus during contextual learning. Nat. Neurosci., 2000, 3(6), 533-535.
64. Mizuno, M.; Yamada, K.; Olariu, A.; Nawa, H.; Nabeshima, T. Involvement of brain-derived neurotrophic factor in spatial memory formation and maintenance in a radial arm maze test in rats. J. Neurosci., 2000, 20(18), 7116-7121.
65. Laske, C.; Stransky, E.; Leyhe, T.; Eschweiler, G. W.; Schott, K.; Langer, H.; Gawaz, M. Decreased brain-derived neurotrophic factor (BDNF)-and beta-thromboglobulin (beta-TG)-blood levels in Alzheimer's disease. Thromb. Haemost., 2006, 96(1), 102-103.
66. O'Bryant, S. E.; Hobson, V.; Hall, J. R.; Waring, S. C.; Chan, W.; Massman, P.; Lacritz, L.; Cullum, C. M.; Diaz-Arrastia, R. Texas Alzheimer's Research, C., Brain-derived neurotrophic factor levels in Alzheimer's disease. J. Alzheimers Dis., 2009, 17(2), 337-341.
67. O'Bryant, S. E.; Hobson, V. L.; Hall, J. R.; Barber, R. C.; Zhang, S.; Johnson, L.; Diaz-Arrastia, R. Texas Alzheimer's Research, C., Serum brain-derived neurotrophic factor levels are specifically associated with memory performance among Alzheimer's disease cases. Dement. Geriatr. Cogn. Disord., 2011, 31(1), 31-36.
68. Qin, X. Y.; Cao, C.; Cawley, N. X.; Liu, T. T.; Yuan, J.; Loh, Y. P.; Cheng, Y. Decreased peripheral brain-derived neurotrophic factor levels in Alzheimer's disease: A metaanalysis study (N=7277). Mol. Psychiatry, 2016. [Epub ahead of print].
69. Kandel, E. R. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. Mol. Brain, 2012, 5, 14.
70. Montminy, M. Transcriptional regulation by cyclic AMP. Annu. Rev. Biochem., 1997, 66, 807-822.
71. Johannessen, M.; Delghandi, M. P.; Moens, U. What turns CREB on? Cell Signal, 2004, 16(11), 1211-1227.
72. Paul, C.; Stratil, C.; Hofmann, F.; Kleppisch, T. cGMPdependent protein kinase type I promotes CREB/CREmediated gene expression in neurons of the lateral amygdala. Neurosci. Lett., 2010, 473(2), 82-86.
73. Garthwaite, J. Concepts of neural nitric oxide-mediated transmission. Eur. J. Neurosci., 2008, 27(11), 2783-2802.
74. Paul, C.; Schoberl, F.; Weinmeister, P.; Micale, V.; Wotjak, C. T.; Hofmann, F.; Kleppisch, T. Signaling through cGMPdependent protein kinase I in the amygdala is critical for auditory-cued fear memory and long-term potentiation. J. Neurosci., 2008, 28(52), 14202-14212.
75. Kleppisch, T.; Wolfsgruber, W.; Feil, S.; Allmann, R.; Wotjak, C. T.; Goebbels, S.; Nave, K. A.; Hofmann, F.; Feil, R. Hippocampal cGMP-dependent protein kinase I supports an age-and protein synthesis-dependent component of longterm potentiation but is not essential for spatial reference and contextual memory. J. Neurosci., 2003, 23(14), 6005-6012.
76. Adams, J. P.; Roberson, E. D.; English, J. D.; Selcher, J. C.; Sweatt, J. D. MAPK regulation of gene expression in the central nervous system. Acta Neurobiol. Exp. (Wars), 2000, 60(3), 377-394.
77. Lu, Y. F.; Kandel, E. R.; Hawkins, R. D. Nitric oxide signaling contributes to late-phase LTP and CREB phosphorylation in the hippocampus. J. Neurosci., 1999, 19(23), 10250-10261.
78. Ota, K. T.; Pierre, V. J.; Ploski, J. E.; Queen, K.; Schafe, G. E. The NO-cGMP-PKG signaling pathway regulates synaptic plasticity and fear memory consolidation in the lateral amygdala via activation of ERK/MAP kinase. Learn Mem., 2008, 15(10), 792-805.
79. Garthwaite, J. Glutamate, nitric oxide and cell-cell signalling in the nervous system. Trends Neurosci., 1991, 14(2), 60-67.
80. VandeVrede, L.; Abdelhamid, R.; Qin, Z.; Choi, J.; Piyankarage, S.; Luo, J.; Larson, J.; Bennett, B. M.; Thatcher, G. R. An NO donor approach to neuroprotective and procognitive estrogen therapy overcomes loss of NO synthase function and potentially thrombotic risk. PLoS One, 2013, 8(8), e70740.
81. Bon, C. L.; Garthwaite, J. On the role of nitric oxide in hippocampal long-term potentiation. J. Neurosci., 2003, 23(5), 1941-1948.
82. Izumi, Y.; Tokuda, K.; Zorumski, C. F. Long-term potentiation inhibition by low-level N-methyl-D-aspartate receptor activation involves calcineurin, nitric oxide, and p38 mitogen-activated protein kinase. Hippocampus, 2008, 18(3), 258-265.
83. Qiu, D. L.; Knopfel, T., An NMDA receptor/nitric oxide cascade in presynaptic parallel fiber-Purkinje neuron longterm potentiation. J. Neurosci., 2007, 27(13), 3408-3415.
84. Tamagnini, F.; Barker, G.; Warburton, E. C.; Burattini, C.; Aicardi, G.; Bashir, Z. I. Nitric oxide-dependent long-term depression but not endocannabinoid-mediated long-term potentiation is crucial for visual recognition memory. J. Physiol., 2013, 591(16), 3963-3979.
85. Ratnayaka, A.; Marra, V.; Bush, D.; Burden, J. J.; Branco, T.; Staras, K. Recruitment of resting vesicles into recycling pools supports NMDA receptor-dependent synaptic potentiation in cultured hippocampal neurons. J. Physiol., 2012, 590(7), 1585-1597.
86. Bernabeu, R.; Schmitz, P.; Faillace, M. P.; Izquierdo, I.; Medina, J. H. Hippocampal cGMP and cAMP are differentially involved in memory processing of inhibitory avoidance learning. Neuroreport., 1996, 7(2), 585-588.
87. Matsumoto, Y.; Unoki, S.; Aonuma, H.; Mizunami, M. Critical role of nitric oxide-cGMP cascade in the formation of cAMP-dependent long-term memory. Learn Mem., 2006, 13(1), 35-44.
88. Rutten, K.; Prickaerts, J.; Hendrix, M.; van der Staay, F. J.; Sik, A.; Blokland, A. Time-dependent involvement of cAMP and cGMP in consolidation of object memory: studies using selective phosphodiesterase type 2, 4 and 5 inhibitors. Eur. J. Pharmacol., 2007, 558(1-3), 107-112.
89. Bollen, E.; Puzzo, D.; Rutten, K.; Privitera, L.; De Vry, J.; Vanmierlo, T.; Kenis, G.; Palmeri, A.; D'Hooge, R.; Balschun, D.; Steinbusch, H. M.; Blokland, A.; Prickaerts, J. Improved long-term memory via enhancing cGMP-PKG signaling requires cAMP-PKA signaling. Neuropsychopharmacology, 2014, 39(11), 2497-2505.
90. Chalimoniuk, M.; Strosznajder, J. B. Aging modulates nitric oxide synthesis and cGMP levels in hippocampus and cerebellum. Effects of amyloid beta peptide. Mol. Chem. Neuropathol., 1998, 35(1-3), 77-95.
91. Jacoby, S.; Sims, R. E.; Hartell, N. A. Nitric oxide is required for the induction and heterosynaptic spread of longterm potentiation in rat cerebellar slices. J. Physiol., 2001, 535(Pt 3), 825-839.
92. Ogasawara, H.; Doi, T.; Doya, K.; Kawato, M. Nitric oxide regulates input specificity of long-term depression and context dependence of cerebellar learning. PLoS Comput. Biol., 2007, 3(1), e179.
93. Schafe, G. E.; Bauer, E. P.; Rosis, S.; Farb, C. R.; Rodrigues, S. M.; LeDoux, J. E. Memory consolidation of Pavlovian fear conditioning requires nitric oxide signaling in the lateral amygdala. Eur. J. Neurosci., 2005, 22(1), 201-211.
94. Phillips, K. G.; Hardingham, N. R.; Fox, K. Postsynaptic action potentials are required for nitric-oxide-dependent long-term potentiation in CA1 neurons of adult GluR1 knock-out and wild-type mice. J. Neurosci., 2008, 28(52), 14031-14041.
95. Blackshaw, S.; Eliasson, M. J.; Sawa, A.; Watkins, C. C.; Krug, D.; Gupta, A.; Arai, T.; Ferrante, R. J.; Snyder, S. H. Species, strain and developmental variations in hippocampal neuronal and endothelial nitric oxide synthase clarify discrepancies in nitric oxide-dependent synaptic plasticity. Neuroscience, 2003, 119(4), 979-990.
96. Di, S.; Maxson, M. M.; Franco, A.; Tasker, J. G. Glucocorticoids regulate glutamate and GABA synapse-specific retrograde transmission via divergent nongenomic signaling pathways. J. Neurosci., 2009, 29(2), 393-401.
97. Hardingham, N.; Fox, K. The role of nitric oxide and GluR1 in presynaptic and postsynaptic components of neocortical potentiation. J. Neurosci., 2006, 26(28), 7395-7404.
98. Volgushev, M.; Balaban, P.; Chistiakova, M.; Eysel, U. T. Retrograde signalling with nitric oxide at neocortical synapses. Eur. J. Neurosci., 2000, 12(12), 4255-4267.
99. Szabadits, E.; Cserep, C.; Ludanyi, A.; Katona, I.; Gracia-Llanes, J.; Freund, T. F.; Nyiri, G. Hippocampal GABAergic synapses possess the molecular machinery for retrograde nitric oxide signaling. J. Neurosci., 2007, 27(30), 8101-8111.
100. Nugent, F. S.; Penick, E. C.; Kauer, J. A. Opioids block longterm potentiation of inhibitory synapses. Nature, 2007, 446(7139), 1086-1090.
101. Saavedra, A.; Giralt, A.; Arumi, H.; Alberch, J.; Perez-Navarro, E. Regulation of hippocampal cGMP levels as a candidate to treat cognitive deficits in Huntington's disease. PLoS One, 2013, 8(9), e73664.
102. Ugarte, A.; Gil-Bea, F.; Garcia-Barroso, C.; Cedazo-Minguez, A.; Ramirez, M. J.; Franco, R.; Garcia-Osta, A.; Oyarzabal, J.; Cuadrado-Tejedor, M., Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease. Neuropathol. Appl. Neurobiol., 2015, 41(4), 471-482.
103. Bollen, E.; Prickaerts, J., Phosphodiesterases in neurodegenerative disorders. IUBMB Life, 2012, 64(12), 965-970.
104. Paakkari, I.; Lindsberg, P. Nitric oxide in the central nervous system. Ann. Med., 1995, 27(3), 369-377.
105. Linares, D.; Taconis, M.; Mana, P.; Correcha, M.; Fordham, S.; Staykova, M.; Willenborg, D. O. Neuronal nitric oxide synthase plays a key role in CNS demyelination. J. Neurosci., 2006, 26(49), 12672-12681.
106. Heneka, M. T.; Feinstein, D. L. Expression and function of inducible nitric oxide synthase in neurons. J. Neuroimmunol., 2001, 114(1-2), 8-18.
107. Brown, G. C.; Neher, J. J. Inflammatory neurodegeneration and mechanisms of microglial killing of neurons. Mol. Neurobiol., 2010, 41(2-3), 242-247.
108. Gargiulo, L.; Bermejo, M.; Liras, A. Reduced neuronal nitric oxide synthetase and c-protein kinase levels in Alzheimer's disease. Rev. Neurol., 2000, 30(4), 301-303.
109. Luth, H. J.; Holzer, M.; Gartner, U.; Staufenbiel, M.; Arendt, T. Expression of endothelial and inducible NOSisoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res., 2001, 913(1), 57-67.
110. Norris, P. J.; Faull, R. L.; Emson, P. C. Neuronal nitric oxide synthase (nNOS) mRNA expression and NADPHdiaphorase staining in the frontal cortex, visual cortex and hippocampus of control and Alzheimer's disease brains. Brain Res. Mol. Brain Res., 1996, 41(1-2), 36-49.
111. Venturini, G.; Colasanti, M.; Persichini, T.; Fioravanti, E.; Ascenzi, P.; Palomba, L.; Cantoni, O.; Musci, G. Betaamyloid inhibits NOS activity by subtracting NADPH availability. FASEB J., 2002, 16(14), 1970-1972.
112. Domek-Lopacinska, K. U.; Strosznajder, J. B. Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease. Mol. Neurobiol., 2010, 41(2-3), 129-137.
113. Tran, M. H.; Yamada, K.; Olariu, A.; Mizuno, M.; Ren, X. H.; Nabeshima, T. Amyloid beta-peptide induces nitric oxide production in rat hippocampus: Association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J., 2001, 15(8), 1407-1409.
114. Wong, A.; Luth, H. J.; Deuther-Conrad, W.; Dukic-Stefanovic, S.; Gasic-Milenkovic, J.; Arendt, T.; Munch, G. Advanced glycation endproducts co-localize with inducible nitric oxide synthase in Alzheimer's disease. Brain Res., 2001, 920(1-2), 32-40.
115. Xie, Z.; Wei, M.; Morgan, T. E.; Fabrizio, P.; Han, D.; Finch, C. E.; Longo, V. D. Peroxynitrite mediates neurotoxicity of amyloid beta-peptide1-42-and lipopolysaccharideactivated microglia. J. Neurosci., 2002, 22(9), 3484-3492.
116. Haas, J.; Storch-Hagenlocher, B.; Biessmann, A.; Wildemann, B. Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with betaamyloid 1-42 in vitro. Neurosci. Lett., 2002, 322(2), 121-125.
117. Monsonego, A.; Imitola, J.; Zota, V.; Oida, T.; Weiner, H. L. Microglia-mediated nitric oxide cytotoxicity of T cells following amyloid beta-peptide presentation to Th1 cells. J. Immunol., 2003, 171(5), 2216-2224.
118. Wang, Q.; Rowan, M. J.; Anwyl, R. Beta-amyloid-mediated inhibition of NMDA receptor-dependent long-term potentiation induction involves activation of microglia and stimulation of inducible nitric oxide synthase and superoxide. J. Neurosci., 2004, 24(27), 6049-6056.
119. Colton, C. A.; Vitek, M. P.; Wink, D. A.; Xu, Q.; Cantillana, V.; Previti, M. L.; Van Nostrand, W. E.; Weinberg, J. B.; Dawson, H., NO synthase 2 (NOS2) deletion promotes multiple pathologies in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006, 103(34), 12867-12872.
120. Colton, C. A.; Wilcock, D. M.; Wink, D. A.; Davis, J.; Van Nostrand, W. E.; Vitek, M. P. The effects of NOS2 gene deletion on mice expressing mutated human AbetaPP. J. Alzheimers Dis., 2008, 15(4), 571-587.
121. Reynolds, J. N.; Bennett, B. M.; Boegman, R. J.; Jhamandas, K.; Ratz, J. D.; Zavorin, S. I.; Scutaru, D.; Dumitrascu, A.; Thatcher, G. R. J., Neuroprotection against ischemic brain injury conferred by a novel nitrate ester. Bioorg. Med. Chem. Lett., 2002, 12(20), 2863-2866.
122. Nicolescu, A. C.; Reynolds, J. N.; Barclay, L. R.; Thatcher, G. R. J. Organic nitrites and NO: inhibition of lipid peroxidation and radical reactions. Chem. Res. Toxicol., 2004, 17(2), 185-196.
123. Wilcock, D. M.; Lewis, M. R.; Van Nostrand, W. E.; Davis, J.; Previti, M. L.; Gharkholonarehe, N.; Vitek, M. P.; Colton, C. A. Progression of amyloid pathology to Alzheimer's disease pathology in an amyloid precursor protein transgenic mouse model by removal of nitric oxide synthase 2. J. Neurosci., 2008, 28(7), 1537-1545.
124. Austin, S. A.; Santhanam, A. V.; Hinton, D. J.; Choi, D. S.; Katusic, Z. S. Endothelial nitric oxide deficiency promotes Alzheimer's disease pathology. J. Neurochem., 2013, 127(5), 691-700.
125. Doreulee, N.; Sergeeva, O. A.; Yanovsky, Y.; Chepkova, A. N.; Selbach, O.; Godecke, A.; Schrader, J.; Haas, H. L. Cortico-striatal synaptic plasticity in endothelial nitric oxide synthase deficient mice. Brain Res., 2003, 964(1), 159-163.
126. de la Torre, J. C.; Aliev, G. Inhibition of vascular nitric oxide after rat chronic brain hypoperfusion: spatial memory and immunocytochemical changes. J. Cereb. Blood Flow Metab., 2005, 25(6), 663-672.
127. McCarty, M. F. Vascular nitric oxide may lessen Alzheimer's risk. Med. Hypotheses, 1998, 51(6), 465-476.
128. Lamoke, F.; Mazzone, V.; Persichini, T.; Maraschi, A.; Harris, M. B.; Venema, R. C.; Colasanti, M.; Gliozzi, M.; Muscoli, C.; Bartoli, M.; Mollace, V. Amyloid beta peptide-induced inhibition of endothelial nitric oxide production involves oxidative stress-mediated constitutive eNOS/ HSP90 interaction and disruption of agonist-mediated Akt activation. J. Neuroinflammation, 2015, 12, 84.
129. Vandevrede, L.; Tavassoli, E.; Luo, J.; Qin, Z.; Yue, L.; Pepperberg, D. R.; Thatcher, G. R. Novel analogues of chlormethiazole are neuroprotective in four cellular models of neurodegeneration by a mechanism with variable dependence on GABA(A) receptor potentiation. Br. J. Pharmacol., 2014, 171(2), 389-402.
130. Luo, J.; Lee, S. H.; VandeVrede, L.; Qin, Z.; Ben Aissa, M.; Larson, J.; Teich, A. F.; Arancio, O.; D'Souza, Y.; Elharram, A.; Koster, K.; Tai, L. M.; LaDu, M. J.; Bennett, B. M.; Thatcher, G. R. A multifunctional therapeutic approach to disease modification in multiple familial mouse models and a novel sporadic model of Alzheimer's disease. Mol. Neurodegener., 2016, 11, 35.
131. Luo, J.; Lee, S. H.; VandeVrede, L.; Qin, Z.; Piyankarage, S.; Tavassoli, E.; Asghodom, R. T.; Ben Aissa, M.; Fa, M.; Arancio, O.; Yue, L.; Pepperberg, D. R.; Thatcher, G. R. Reengineering a neuroprotective, clinical drug as a procognitive agent with high in vivo potency and with GABAA potentiating activity for use in dementia. BMC Neurosci., 2015, 16, 67.
132. Bonkale, W. L.; Winblad, B.; Ravid, R.; Cowburn, R. F. Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease. Neurosci. Lett., 1995, 187(1), 5-8.
133. Baltrons, M. A.; Pedraza, C. E.; Heneka, M. T.; Garcia, A. Beta-amyloid peptides decrease soluble guanylyl cyclase expression in astroglial cells. Neurobiol. Dis., 2002, 10(2), 139-149.
134. Bolla, M.; Almirante, N.; Benedini, F. Therapeutic potential of nitrate esters of commonly used drugs. Curr. Top. Med. Chem., 2005, 5(7), 707-720.
135. Thatcher, G. R., An introduction to NO-related therapeutic agents. Curr. Top. Med. Chem., 2005, 5(7), 597-601.
136. Thatcher, G. R. J. In: Radicals for Life: The Various Forms of Nitric Oxide. van Fassen, E.; Vanin, A., Eds.; Elsevier Science: Amsterdam, 2007.
137. Thatcher, G. R. J.; Weldon, H. NO problem for nitroglycerin: organic nitrate chemistry and therapy. Chem. Soc. Rev., 1998, 27(5), 331-337.
138. Thatcher, G. R. J.; Nicolescu, A. C.; Bennett, B. M.; Toader, V. Nitrates and NO release: Contemporary aspects in biological and medicinal chemistry. Free Radic. Biol. Med., 2004, 37(8), 1122-1143.
139. Thatcher, G. R. J.; Bennett, B. M.; Reynolds, J. N. NO chimeras as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res., 2006, 3(3), 237-245.
140. Follmann, M.; Griebenow, N.; Hahn, M. G.; Hartung, I.; Mais, F. J.; Mittendorf, J.; Schafer, M.; Schirok, H.; Stasch, J. P.; Stoll, F.; Straub, A. The chemistry and biology of soluble guanylate cyclase stimulators and activators. Angew. Chem. Int. Ed Engl., 2013, 52(36), 9442-9462.
141. Evgenov, O. V.; Pacher, P.; Schmidt, P. M.; Hasko, G.; Schmidt, H. H.; Stasch, J. P. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat. Rev. Drug Discov., 2006, 5(9), 755-768.
142. Foxton, R. H.; Land, J. M.; Heales, S. J. Tetrahydrobiopterin availability in Parkinson's and Alzheimer's disease; potential pathogenic mechanisms. Neurochem. Res., 2007, 32(4-5), 751-756.
143. Santhanam, A. V.; d'Uscio, L. V.; He, T.; Das, P.; Younkin, S. G.; Katusic, Z. S. Uncoupling of endothelial nitric oxide synthase in cerebral vasculature of Tg2576 mice. J. Neurochem., 2015, 134(6), 1129-1138.
144. Curtis, E.; Hsu, L. L.; Noguchi, A. C.; Geary, L.; Shiva, S. Oxygen regulates tissue nitrite metabolism. Antioxid. Redox Signal., 2012, 17(7), 951-961.
145. Cosby, K.; Partovi, K. S.; Crawford, J. H.; Patel, R. P.; Reiter, C. D.; Martyr, S.; Yang, B. K.; Waclawiw, M. A.; Zalos, G.; Xu, X.; Huang, K. T.; Shields, H.; Kim-Shapiro, D. B.; Schechter, A. N.; Cannon, R. O., 3rd; Gladwin, M. T. Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat. Med., 2003, 9(12), 1498-1505.
146. Lundberg, J. O.; Govoni, M., Inorganic nitrate is a possible source for systemic generation of nitric oxide. Free Radic. Biol. Med., 2004, 37(3), 395-400.
147. Lundberg, J. O.; Weitzberg, E. NO generation from nitrite and its role in vascular control. Arterioscler. Thromb. Vasc. Biol., 2005, 25(5), 915-922.
148. Lefer, D. J., Nitrite therapy for protection against ischemiareperfusion injury. Am. J. Physiol. Renal Physiol., 2006, 290(4), F777-F778.
149. Gonzalez, F. M.; Shiva, S.; Vincent, P. S.; Ringwood, L. A.; Hsu, L. Y.; Hon, Y. Y.; Aletras, A. H.; Cannon, R. O., 3rd; Gladwin, M. T.; Arai, A. E. Nitrite anion provides potent cytoprotective and antiapoptotic effects as adjunctive therapy to reperfusion for acute myocardial infarction. Circulation, 2008, 117(23), 2986-2994.
150. Sinha, S. S.; Shiva, S.; Gladwin, M. T. Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation. Trends Cardiovasc. Med., 2008, 18(5), 163-172.
151. Shiva, S.; Sack, M. N.; Greer, J. J.; Duranski, M.; Ringwood, L. A.; Burwell, L.; Wang, X.; MacArthur, P. H.; Shoja, A.; Raghavachari, N.; Calvert, J. W.; Brookes, P. S.; Lefer, D. J.; Gladwin, M. T. Nitrite augments tolerance to ischemia/ reperfusion injury via the modulation of mitochondrial electron transfer. J. Exp. Med., 2007, 204(9), 2089-2102.
152. Kumar, D.; Branch, B. G.; Pattillo, C. B.; Hood, J.; Thoma, S.; Simpson, S.; Illum, S.; Arora, N.; Chidlow, J. H., Jr.; Langston, W.; Teng, X.; Lefer, D. J.; Patel, R. P.; Kevil, C. G. Chronic sodium nitrite therapy augments ischemiainduced angiogenesis and arteriogenesis. Proc. Natl. Acad. Sci. U SA, 2008, 105(21), 7540-7545.
153. Schiefer, I. T.; Vandevrede, L.; Fa, M.; Arancio, O.; Thatcher, G. R. Furoxans (1, 2, 5-Oxadiazole-N-Oxides) as Novel NO Mimetic Neuroprotective and Procognitive Agents. J. Med. Chem., 2012, 55(7), 3076-3087.
154. Thatcher, G. R.; Bennett, B. M.; Dringenberg, H. C.; Reynolds, J. N. Novel nitrates as NO mimetics directed at Alzheimer's disease. J. Alzheimers Dis., 2004, 6(6 Suppl), S75-s84.
155. Qin, Z.; Luo, J.; VandeVrede, L.; Tavassoli, E.; Fa, M.; Teich, A. F.; Arancio, O.; Thatcher, G. R., Design and synthesis of neuroprotective methylthiazoles and modification as NO-chimeras for neurodegenerative therapy. J. Med. Chem., 2012, 55(15), 6784-6801.
156. Abdul-Hay, S.; Schiefer, I. T.; Chandrasena, R. E.; Li, M.; Abdelhamid, R.; Wang, Y. T.; Tavassoli, E.; Michalsen, B.; Asghodom, R. T.; Luo, J.; Thatcher, G. R. NO-SSRIs: Nitric Oxide Chimera Drugs Incorporating a Selective Serotonin Reuptake Inhibitor. ACS Med. Chem. Lett., 2011, 2(9), 656-661.
157. Abdul-Hay, S. O.; Luo, J.; Ashghodom, R. T.; Thatcher, G. R. NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade. J. Neurochem., 2009, 111(3), 766-776.
158. Lee, Y. J.; Han, S. B.; Nam, S. Y.; Oh, K. W.; Hong, J. T. Inflammation and Alzheimer's disease. Arch. Pharm. Res., 2010, 33(10), 1539-1556.
159. Tai, L. M.; Ghura, S.; Koster, K. P.; Liakaite, V.; Maienschein-Cline, M.; Kanabar, P.; Collins, N.; Ben-Aissa, M.; Lei, A. Z.; Bahroos, N.; Green, S. J.; Hendrickson, B.; Van Eldik, L. J.; LaDu, M. J. APOE-modulated Abeta-induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. J. Neurochem., 2015, 133(4), 465-488.
160. Bales, K. R.; Du, Y.; Holtzman, D.; Cordell, B.; Paul, S. M. Neuroinflammation and Alzheimer's disease: critical roles for cytokine/Abeta-induced glial activation, NF-kappaB, and apolipoprotein E. Neurobiol. Aging, 2000, 21(3), 427-432; discussion 451-423.
161. Eikelenboom, P.; Veerhuis, R.; Scheper, W.; Rozemuller, A. J.; van Gool, W. A.; Hoozemans, J. J. The significance of neuroinflammation in understanding Alzheimer's disease. J. Neural. Transm., 2006, 113(11), 1685-1695.
162. Lleo, A.; Galea, E.; Sastre, M. Molecular targets of nonsteroidal anti-inflammatory drugs in neurodegenerative diseases. Cell. Mol. Life Sci., 2007, 64(11), 1403-1418.
163. Van Eldik, L. J.; Thompson, W. L.; Ralay Ranaivo, H.; Behanna, H. A.; Martin Watterson, D. Glia proinflammatory cytokine upregulation as a therapeutic target for neurodegenerative diseases: function-based and target-based discovery approaches. Int. Rev. Neurobiol., 2007, 82, 277-296.
164. Weggen, S.; Eriksen, J. L.; Das, P.; Sagi, S. A.; Wang, R.; Pietrzik, C. U.; Findlay, K. A.; Smith, T. E.; Murphy, M. P.; Bulter, T.; Kang, D. E.; Marquez-Sterling, N.; Golde, T. E.; Koo, E. H. A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity. Nature, 2001, 414 (6860), 212-216.
165. Lim, G. P.; Yang, F.; Chu, T.; Chen, P.; Beech, W.; Teter, B.; Tran, T.; Ubeda, O.; Ashe, K. H.; Frautschy, S. A.; Cole, G. M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci., 2000, 20 (15), 5709-5714.
166. Jantzen, P. T.; Connor, K. E.; DiCarlo, G.; Wenk, G. L.; Wallace, J. L.; Rojiani, A. M.; Coppola, D.; Morgan, D.; Gordon, M. N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci., 2002, 22(6), 2246-2254.
167. Yan, Q.; Zhang, J.; Liu, H.; Babu-Khan, S.; Vassar, R.; Biere, A. L.; Citron, M.; Landreth, G. Anti-inflammatory drug therapy alters beta-amyloid processing and deposition in an animal model of Alzheimer's disease. J. Neurosci., 2003, 23(20), 7504-7509.
168. Beher, D.; Clarke, E. E.; Wrigley, J. D.; Martin, A. C.; Nadin, A.; Churcher, I.; Shearman, M. S. Selected non-steroidal anti-inflammatory drugs and their derivatives target gamma-secretase at a novel site. Evidence for an allosteric mechanism. J. Biol. Chem., 2004, 279(42), 43419-43426.
169. Lleo, A.; Berezovska, O.; Herl, L.; Raju, S.; Deng, A.; Bacskai, B. J.; Frosch, M. P.; Irizarry, M.; Hyman, B. T. Nonsteroidal anti-inflammatory drugs lower Abeta42 and change presenilin 1 conformation. Nat. Med., 2004, 10(10), 1065-1066.
170. Sastre, M.; Dewachter, I.; Rossner, S.; Bogdanovic, N.; Rosen, E.; Borghgraef, P.; Evert, B. O.; Dumitrescu-Ozimek, L.; Thal, D. R.; Landreth, G.; Walter, J.; Klockgether, T.; van Leuven, F.; Heneka, M. T. Nonsteroidal antiinflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(2), 443-448.
171. Zhou, Y.; Su, Y.; Li, B.; Liu, F.; Ryder, J. W.; Wu, X.; Gonzalez-DeWhitt, P. A.; Gelfanova, V.; Hale, J. E.; May, P. C.; Paul, S. M.; Ni, B. Nonsteroidal anti-inflammatory drugs can lower amyloidogenic Abeta42 by inhibiting Rho. Science, 2003, 302(5648), 1215-1217.
172. Kukar, T. L.; Ladd, T. B.; Bann, M. A.; Fraering, P. C.; Narlawar, R.; Maharvi, G. M.; Healy, B.; Chapman, R.; Welzel, A. T.; Price, R. W.; Moore, B.; Rangachari, V.; Cusack, B.; Eriksen, J.; Jansen-West, K.; Verbeeck, C.; Yager, D.; Eckman, C.; Ye, W.; Sagi, S.; Cottrell, B. A.; Torpey, J.; Rosenberry, T. L.; Fauq, A.; Wolfe, M. S.; Schmidt, B.; Walsh, D. M.; Koo, E. H.; Golde, T. E., Substrate-targeting gamma-secretase modulators. Nature, 2008, 453(7197), 925-929.
173. James, D. S. The multisystem adverse effects of NSAID therapy. J. Am. Osteopath. Assoc., 1999, 99 (11 Suppl), S1-7.
174. Laine, L. The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. Semin. Arthritis Rheum., 2002, 32(3 Suppl 1), 25-32.
175. Aisen, P. S.; Schafer, K. A.; Grundman, M.; Pfeiffer, E.; Sano, M.; Davis, K. L.; Farlow, M. R.; Jin, S.; Thomas, R. G.; Thal, L. J. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA, 2003, 289(21), 2819-2826.
176. Aisen, P. S.; Thal, L. J.; Ferris, S. H.; Assaid, C.; Nessly, M. L.; Giuliani, M. J.; Lines, C. R.; Norman, B. A.; Potter, W. Z. Rofecoxib in patients with mild cognitive impairment: further analyses of data from a randomized, double-blind, trial. Curr. Alzheimer Res., 2008, 5(1), 73-82.
177. Soininen, H.; West, C.; Robbins, J.; Niculescu, L. Longterm efficacy and safety of celecoxib in Alzheimer's disease. Dement. Geriatr. Cogn. Disord., 2007, 23(1), 8-21.
178. Kukar, T.; Murphy, M. P.; Eriksen, J. L.; Sagi, S. A.; Weggen, S.; Smith, T. E.; Ladd, T.; Khan, M. A.; Kache, R.; Beard, J.; Dodson, M.; Merit, S.; Ozols, V. V.; Anastasiadis, P. Z.; Das, P.; Fauq, A.; Koo, E. H.; Golde, T. E. Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat. Med., 2005, 11(5), 545-550.
179. Green, R. C.; Schneider, L. S.; Amato, D. A.; Beelen, A. P.; Wilcock, G.; Swabb, E. A.; Zavitz, K. H.; Tarenflurbil Phase 3 Study, G. Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: A randomized controlled trial. JAMA, 2009, 302(23), 2557-2564.
180. Marder, K. Tarenflurbil in patients with mild Alzheimer's disease. Curr. Neurol. Neurosci. Rep., 2010, 10(5), 336-337.
181. Lanas, A. Role of nitric oxide in the gastrointestinal tract. Arthritis Res. Ther., 2008, 10(Suppl 2), S4.
182. Calatayud, S.; Barrachina, D.; Esplugues, J. V. Nitric oxide: relation to integrity, injury, and healing of the gastric mucosa. Microsc. Res. Tech., 2001, 53(5), 325-335.
183. Anning, P. B.; Coles, B.; Morton, J.; Wang, H.; Uddin, J.; Morrow, J. D.; Dey, S. K.; Marnett, L. J.; O'Donnell, V. B. Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors. Blood, 2006, 108(13), 4059-4062.
184. Thatcher, G. R.; Bennett, B. M.; Reynolds, J. N. Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease. Curr. Alzheimer Res., 2005, 2(2), 171-182.
185. Wenk, G. L.; McGann-Gramling, K.; Hauss-Wegrzyniak, B.; Ronchetti, D.; Maucci, R.; Rosi, S.; Gasparini, L.; Ongini, E. Attenuation of chronic neuroinflammation by a nitric oxide-releasing derivative of the antioxidant ferulic acid. J. Neurochem., 2004, 89(2), 484-493.
186. Burgaud, J. L.; Riffaud, J. P.; Del Soldato, P. Nitric-oxide releasing molecules: A new class of drugs with several major indications. Curr. Pharm. Des., 2002, 8(3), 201-213.
187. Eriksen, J. L.; Sagi, S. A.; Smith, T. E.; Weggen, S.; Das, P.; McLendon, D. C.; Ozols, V. V.; Jessing, K. W.; Zavitz, K. H.; Koo, E. H.; Golde, T. E. NSAIDs and enantiomers of flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J. Clin. Invest., 2003, 112(3), 440-449.
188. Wallace, J. L.; Muscara, M. N.; de Nucci, G.; Zamuner, S.; Cirino, G.; del Soldato, P.; Ongini, E. Gastric tolerability and prolonged prostaglandin inhibition in the brain with a nitric oxide-releasing flurbiprofen derivative, NCX-2216 3-[4-(2-fluoro-alpha-methyl-[1, 1'-biphenyl-4-acetyloxy)-3-methoxyphenyl]-2-prop enoic acid 4-nitrooxy butyl ester]. J. Pharmacol. Exp. Ther., 2004, 309(2), 626-633.
189. van Groen, T.; Kadish, I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Brain Res. Rev., 2005, 48(2), 370-378.
190. Prosperi, C.; Scali, C.; Barba, M.; Bellucci, A.; Giovannini, M. G.; Pepeu, G.; Casamenti, F. Comparison between flurbiprofen and its nitric oxide-releasing derivatives HCT-1026 and NCX-2216 on Abeta(1-42)-induced brain inflammation and neuronal damage in the rat. Int. J. Immunopathol. Pharmacol., 2004, 17(3), 317-330.
191. Christensen, D. D. Changing the course of Alzheimer's disease: Anti-amyloid disease-modifying treatments on the horizon. Prim. Care Companion J. Clin. Psychiatry, 2007, 9(1), 32-41.
192. Peretto, I.; Radaelli, S.; Parini, C.; Zandi, M.; Raveglia, L. F.; Dondio, G.; Fontanella, L.; Misiano, P.; Bigogno, C.; Rizzi, A.; Riccardi, B.; Biscaioli, M.; Marchetti, S.; Puccini, P.; Catinella, S.; Rondelli, I.; Cenacchi, V.; Bolzoni, P. T.; Caruso, P.; Villetti, G.; Facchinetti, F.; Del Giudice, E.; Moretto, N.; Imbimbo, B. P. Synthesis and biological activity of flurbiprofen analogues as selective inhibitors of betaamyloid( 1)(-)(42) secretion. J. Med. Chem., 2005, 48(18), 5705-5720.
193. Imbimbo, B. P.; Giardino, L.; Sivilia, S.; Giuliani, A.; Gusciglio, M.; Pietrini, V.; Del Giudice, E.; D'Arrigo, A.; Leon, A.; Villetti, G.; Calza, L. CHF5074, a novel gammasecretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease. J. Alzheimers Dis., 2010, 20(1), 159-173.
194. Ross, J.; Sharma, S.; Winston, J.; Nunez, M.; Bottini, G.; Franceschi, M.; Scarpini, E.; Frigerio, E.; Fiorentini, F.; Fernandez, M.; Sivilia, S.; Giardino, L.; Calza, L.; Norris, D.; Cicirello, H.; Casula, D.; Imbimbo, B. P. CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: A 12-week, double-blind, placebo-controlled study. Curr. Alzheimer Res., 2013, 10(7), 742-753.
195. Schiefer, I. T.; Abdul-Hay, S.; Wang, H.; Vanni, M.; Qin, Z.; Thatcher, G. R. Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates. J. Med. Chem., 2011, 54(7), 2293-2306.
196. van Groen, T.; Kadish, I. Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. Brain Res. Brain Res. Rev., 2005, 48(2), 370-378.
197. Jantzen, P. T.; Connor, K. E.; DiCarlo, G.; Wenk, G. L.; Wallace, J. L.; Rojiani, A. M.; Coppola, D.; Morgan, D.; Gordon, M. N. Microglial activation and beta-amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice. J. Neurosci., 2002, 22(6), 2246-2254.
198. Velazquez, C. A.; Chen, Q. H.; Citro, M. L.; Keefer, L. K.; Knaus, E. E. Second-generation aspirin and indomethacin prodrugs possessing an O(2)-(acetoxymethyl)-1-(2-carboxypyrrolidin-1-yl)diazenium-1, 2-diolate nitric oxide donor moiety: design, synthesis, biological evaluation, and nitric oxide release studies. J. Med. Chem., 2008, 51(6), 1954-1961.
199. de Carvalho, P. S.; Marostica, M.; Gambero, A.; Pedrazzoli, J., Jr. Synthesis and pharmacological characterization of a novel nitric oxide-releasing diclofenac derivative containing a benzofuroxan moiety. Eur. J. Med. Chem., 2010, 45(6), 2489-2493.
200. Ballard, C. G. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition. Eur. Neurol., 2002, 47(1), 64-70.
201. Kopf, S. R.; Benton, R. S.; Kalfin, R.; Giovannini, M. G.; Pepeu, G. NO synthesis inhibition decreases cortical ACh release and impairs retention of a conditioned response. Brain Res., 2001, 894(1), 141-144.
202. Crismon, M. L. Tacrine: first drug approved for Alzheimer's disease. Ann. Pharmacother., 1994, 28(6), 744-751.
203. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Roegler, C.; Deufel, T.; Fleck, C.; Peng, S.; Zhang, Y.; Lehmann, J. Synthesis and biological evaluation of NOdonor-tacrine hybrids as hepatoprotective anti-Alzheimer drug candidates. J. Med. Chem., 2008, 51(4), 713-716.
204. Fang, L.; Appenroth, D.; Decker, M.; Kiehntopf, M.; Lupp, A.; Peng, S.; Fleck, C.; Zhang, Y.; Lehmann, J. NOdonating tacrine hybrid compounds improve scopolamineinduced cognition impairment and show less hepatotoxicity. J. Med. Chem., 2008, 51(24), 7666-7669.
205. Gracon, S. I.; Knapp, M. J.; Berghoff, W. G.; Pierce, M.; DeJong, R.; Lobbestael, S. J.; Symons, J.; Dombey, S. L.; Luscombe, F. A.; Kraemer, D. Safety of tacrine: clinical trials, treatment IND, and postmarketing experience. Alzheimer Dis. Assoc. Disord., 1998, 12 (2), 93-101.
206. Futter, L. E.; al-Swayeh, O. A.; Moore, P. K. A comparison of the effect of nitroparacetamol and paracetamol on liver injury. Br. J. Pharmacol., 2001, 132, (1), 10-12.
207. Malberg, J. E.; Blendy, J. A., Antidepressant action: To the nucleus and beyond. Trends Pharmacol. Sci., 2005, 26(12), 631-638.
208. D'Souza, Y.; Elharram, A.; Soon-Shiong, R.; Andrew, R. D.; Bennett, B. M. Characterization of Aldh2 (-/-) mice as an age-related model of cognitive impairment and Alzheimer's disease. Mol. Brain, 2015, 8, 27.
209. Ko, F. N.; Wu, C. C.; Kuo, S. C.; Lee, F. Y.; Teng, C. M. YC-1, a novel activator of platelet guanylate cyclase. Blood, 1994, 84 (12), 4226-4233.
210. Hobbs, A. J.; Stasch, J.-P. In: Nitric Oxide (Second Edition); Academic Press: San Diego, 2010, pp. 301-326.
211. Mulsch, A.; Bauersachs, J.; Schafer, A.; Stasch, J. P.; Kast, R.; Busse, R. Effect of YC-1, an NO-independent, superoxide-sensitive stimulator of soluble guanylyl cyclase, on smooth muscle responsiveness to nitrovasodilators. Br. J. Pharmacol., 1997, 120 (4), 681-689.
212. Hoenicka, M.; Becker, E. M.; Apeler, H.; Sirichoke, T.; Schroder, H.; Gerzer, R.; Stasch, J. P. Purified soluble guanylyl cyclase expressed in a baculovirus/Sf9 system: stimulation by YC-1, nitric oxide, and carbon monoxide. J. Mol. Med. (Berl)., 1999, 77(1), 14-23.
213. Artz, J. D.; Toader, V.; Zavorin, S. I.; Bennett, B. M.; Thatcher, G. R., In vitro activation of soluble guanylyl cyclase and nitric oxide release: A comparison of NO donors and NO mimetics. Biochemistry, 2001, 40 (31), 9256-9264.
214. Friebe, A.; Koesling, D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol. Pharmacol., 1998, 53(1), 123-127.
215. Russwurm, M.; Mergia, E.; Mullershausen, F.; Koesling, D. Inhibition of deactivation of NO-sensitive guanylyl cyclase accounts for the sensitizing effect of YC-1. J. Biol. Chem., 2002, 277 (28), 24883-24888.
216. Friebe, A.; Mullershausen, F.; Smolenski, A.; Walter, U.; Schultz, G.; Koesling, D. YC-1 potentiates nitric oxide-and carbon monoxide-induced cyclic GMP effects in human platelets. Mol. Pharmacol., 1998, 54 (6), 962-967.
217. Chien, W. L.; Liang, K. C.; Teng, C. M.; Kuo, S. C.; Lee, F. Y.; Fu, W. M., Enhancement of long-term potentiation by a potent nitric oxide-guanylyl cyclase activator, 3-(5-hydroxymethyl-2-furyl)-1-benzyl-indazole. Mol. Pharmacol., 2003, 63 (6), 1322-1328.
218. Chien, W. L.; Liang, K. C.; Teng, C. M.; Kuo, S. C.; Lee, F. Y.; Fu, W. M. Enhancement of learning behaviour by a potent nitric oxide-guanylate cyclase activator YC-1. Eur. J. Neurosci., 2005, 21(6), 1679-1688.
219. Chien, W. L.; Liang, K. C.; Fu, W. M. Enhancement of active shuttle avoidance response by the NO-cGMP-PKG activator YC-1. Eur. J. Pharmacol., 2008, 590 (1-3), 233-240.
220. Yang, X.; Wang, Y.; Luo, J.; Liu, S.; Yang, Z. Protective effects of YC-1 against glutamate induced PC12 cell apoptosis. Cell Mol. Neurobiol., 2011, 31(2), 303-311.
221. Galle, J.; Zabel, U.; Hubner, U.; Hatzelmann, A.; Wagner, B.; Wanner, C.; Schmidt, H. H. Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity. Br. J. Pharmacol., 1999, 127(1), 195-203.
222. Straub, A.; Stasch, J. P.; Alonso-Alija, C.; Benet-Buchholz, J.; Ducke, B.; Feurer, A.; Furstner, C. NO-independent stimulators of soluble guanylate cyclase. Bioorg. Med. Chem. Lett., 2001, 11(6), 781-784.
223. Stasch, J. P.; Alonso-Alija, C.; Apeler, H.; Dembowsky, K.; Feurer, A.; Minuth, T.; Perzborn, E.; Schramm, M.; Straub, A., Pharmacological actions of a novel NO-independentguanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br. J. Pharmacol., 2002, 135 (2), 333-343.
224. Stasch, J. P.; Dembowsky, K.; Perzborn, E.; Stahl, E.; Schramm, M. Cardiovascular actions of a novel NOindependent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br. J. Pharmacol., 2002, 135(2), 344-355.
225. Bischoff, E.; Stasch, J. P., Effects of the sGC stimulator BAY 41-2272 are not mediated by phosphodiesterase 5 inhibition. Circulation, 2004, 110(12), e320-321; author reply e320-321.
226. Schmidt, P.; Schramm, M.; Schroder, H.; Stasch, J. P., Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase. Eur. J. Pharmacol., 2003, 468, (3), 167-174.
227. Zanfolin, M.; Faro, R.; Araujo, E. G.; Guaraldo, A. M.; Antunes, E.; De Nucci, G. Protective effects of BAY 41-2272 (sGC stimulator) on hypertension, heart, and cardiomyocyte hypertrophy induced by chronic L-NAME treatment in rats. J. Cardiovasc. Pharmacol., 2006, 47(3), 391-395.
228. Masuyama, H.; Tsuruda, T.; Kato, J.; Imamura, T.; Asada, Y.; Stasch, J. P.; Kitamura, K.; Eto, T. Soluble guanylate cyclase stimulation on cardiovascular remodeling in angiotensin II-induced hypertensive rats. Hypertension, 2006, 48(5), 972-978.
229. Deruelle, P.; Balasubramaniam, V.; Kunig, A. M.; Seedorf, G. J.; Markham, N. E.; Abman, S. H. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol. Neonate., 2006, 90(2), 135-144.
230. Straub, A.; Benet-Buckholz, J.; Frode, R.; Kern, A.; Kohlsdorfer, C.; Schmitt, P.; Schwarz, T.; Siefert, H. M.; Stasch, J. P. Metabolites of orally active NO-independent pyrazolopyridine stimulators of soluble guanylate cyclase. Bioorg. Med. Chem., 2002, 10(6), 1711-1717.
231. Khaybullina, D.; Patel, A.; Zerilli, T. Riociguat (adempas): A novel agent for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. P. T., 2014, 39(11), 749-758.
232. Gheorghiade, M.; Greene, S. J.; Butler, J.; Filippatos, G.; Lam, C. S.; Maggioni, A. P.; Ponikowski, P.; Shah, S. J.; Solomon, S. D.; Kraigher-Krainer, E.; Samano, E. T.; Muller, K.; Roessig, L.; Pieske, B.; Investigators, S.-R.; Coordinators, Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The socrates-reduced randomized trial. JAMA, 2015, 314 (21), 2251-2262.
233. Wunder, F.; Stasch, J. P.; Hutter, J.; Alonso-Alija, C.; Huser, J.; Lohrmann, E. A cell-based cGMP assay useful for ultra-high-throughput screening and identification of modulators of the nitric oxide/cGMP pathway. Anal. Biochem., 2005, 339(1), 104-112.
234. Stasch, J. P.; Schmidt, P. M.; Nedvetsky, P. I.; Nedvetskaya, T. Y.; H, S. A.; Meurer, S.; Deile, M.; Taye, A.; Knorr, A.; Lapp, H.; Muller, H.; Turgay, Y.; Rothkegel, C.; Tersteegen, A.; Kemp-Harper, B.; Muller-Esterl, W.; Schmidt, H. H. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J. Clin. Invest., 2006, 116(9), 2552-2561.
235. Boerrigter, G.; Costello-Boerrigter, L. C.; Cataliotti, A.; Lapp, H.; Stasch, J. P.; Burnett, J. C., Jr. Targeting hemeoxidized soluble guanylate cyclase in experimental heart failure. Hypertension, 2007, 49(5), 1128-1133.
236. Reneerkens, O. A.; Rutten, K.; Steinbusch, H. W.; Blokland, A.; Prickaerts, J. Selective phosphodiesterase inhibitors: A promising target for cognition enhancement. Psychopharmacology (Berl), 2009, 202 (1-3), 419-443.
237. Bales, K. R., Plath N., Svenstrup, N., and Menniti, F. S. Phosphodiesterase inhibition to target the synaptic dysfunction in Alzheimer's disease. Top. Med. Chem., 2010, 6, 57-59.
238. Fisher, D. A.; Smith, J. F.; Pillar, J. S.; St Denis, S. H.; Cheng, J. B. Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase. J. Biol. Chem., 1998, 273 (25), 15559-15564.
239. Wunder, F.; Tersteegen, A.; Rebmann, A.; Erb, C.; Fahrig, T.; Hendrix, M. Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol. Pharmacol., 2005, 68(6), 1775-1781.
240. van der Staay, F. J.; Rutten, K.; Barfacker, L.; Devry, J.; Erb, C.; Heckroth, H.; Karthaus, D.; Tersteegen, A.; van Kampen, M.; Blokland, A.; Prickaerts, J.; Reymann, K. G.; Schroder, U. H.; Hendrix, M. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology, 2008, 55 (5), 908-918.
241. Hutson, P. H.; Finger, E. N.; Magliaro, B. C.; Smith, S. M.; Converso, A.; Sanderson, P. E.; Mullins, D.; Hyde, L. A.; Eschle, B. K.; Turnbull, Z.; Sloan, H.; Guzzi, M.; Zhang, X.; Wang, A.; Rindgen, D.; Mazzola, R.; Vivian, J. A.; Eddins, D.; Uslaner, J. M.; Bednar, R.; Gambone, C.; Le-Mair, W.; Marino, M. J.; Sachs, N.; Xu, G.; Parmentier-Batteur, S. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 (6-[(3S, 4S)-4-methyl-1-(pyrimidin-2-ylmethyl) pyrrolidin-3-yl]-1-(tetrahydro-2H-py ran-4-yl)-1, 5-dihydro-4H-pyrazolo[3, 4-d]pyrimidin-4-one) enhances synaptic plasticity and cognitive function in rodents. Neuropharmacology, 2011, 61(4), 665-676.
242. Vardigan, J. D.; Converso, A.; Hutson, P. H.; Uslaner, J. M. The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task. J. Neurogenet., 2011, 25(4), 120-126.
243. Schwam, E. M.; Nicholas, T.; Chew, R.; Billing, C. B.; Davidson, W.; Ambrose, D.; Altstiel, L. D. A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease. Curr. Alzheimer Res., 2014, 11(5), 413-421.
244. Mason, V. L. Alzheimer's Association International Conference on Alzheimer's Disease 2015 (AAIC 2015) (July 18-23, 2015-Washington, D. C., USA). Drugs Today (Barc), 2015, 51 (7), 447-452.
245. Peixoto, C. A.; Nunes, A. K.; Garcia-Osta, A. Phosphodiesterase-5 Inhibitors: Action on the Signaling Pathways of Neuroinflammation, Neurodegeneration, and Cognition. Mediators Inflamm., 2015, 2015, 940207.
246. Francis, S. H.; Corbin, J. D.; Bischoff, E. Cyclic GMPhydrolyzing phosphodiesterases. Handb. Exp. Pharmacol., 2009, 191, 367-408.
247. Cuadrado-Tejedor, M.; Hervias, I.; Ricobaraza, A.; Puerta, E.; Perez-Roldan, J. M.; Garcia-Barroso, C.; Franco, R.; Aguirre, N.; Garcia-Osta, A. Sildenafil restores cognitive function without affecting beta-amyloid burden in a mouse model of Alzheimer's disease. Br. J. Pharmacol., 2011, 164(8), 2029-2041.
248. Reneerkens, O. A.; Rutten, K.; Akkerman, S.; Blokland, A.; Shaffer, C. L.; Menniti, F. S.; Steinbusch, H. W.; Prickaerts, J. Phosphodiesterase type 5 (PDE5) inhibition improves object recognition memory: indications for central and peripheral mechanisms. Neurobiol. Learn. Mem., 2012, 97(4), 370-379.
249. Puzzo, D.; Staniszewski, A.; Deng, S. X.; Privitera, L.; Leznik, E.; Liu, S.; Zhang, H.; Feng, Y.; Palmeri, A.; Landry, D. W.; Arancio, O. Phosphodiesterase 5 inhibition improves synaptic function, memory, and amyloid-beta load inan Alzheimer's disease mouse model. J. Neurosci., 2009, 29 (25), 8075-8086.
250. Garcia-Barroso, C.; Ricobaraza, A.; Pascual-Lucas, M.; Unceta, N.; Rico, A. J.; Goicolea, M. A.; Salles, J.; Lanciego, J. L.; Oyarzabal, J.; Franco, R.; Cuadrado-Tejedor, M.; Garcia-Osta, A. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD. Neuropharmacology, 2013, 64, 114-123.
251. Fiorito, J.; Saeed, F.; Zhang, H.; Staniszewski, A.; Feng, Y.; Francis, Y. I.; Rao, S.; Thakkar, D. M.; Deng, S. X.; Landry, D. W.; Arancio, O. Synthesis of quinoline derivatives: discovery of a potent and selective phosphodiesterase 5 inhibitor for the treatment of Alzheimer's disease. Eur. J. Med. Chem., 2013, 60, 285-294.